The phase 3 EMBER-3 trial is evaluating imlunestrant, a next-generation oral selective estrogen receptor degrader (SERD), alone or in combination…
en_news
The results of the SOLTI-2103 VALENTINE clinical trial demonstrate that the antibody drug conjugate (ADC) patritumab deruxtecan at the standard…
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second-leading cause of cancer-related deaths in Europe by 2040. Unlike other…
The Vall d’Hebron Institute of Oncology (VHIO) has received one of the COFUND grants under the Marie Skłodowska-Curie Actions (MSCA)…
“Maestra con clase” is an initiative created by Mónica Tribó to design materials and products specifically for teachers. In her…
Dr. Jonathan Whitfield and Dr. Mariano Zacarías-Fluck, researchers in the Models of Cancer Therapies Group at VHIO, together with Dr….
Clarivate™ has revealed the annual list of Highly Cited Researchers™ 2024, curated by its experts at the Institute for Scientific…
The p95HER2 protein is found expressed in one third of HER2+ tumors, which represent 4% of all tumors. Led by…
• Endocrine therapy is a type of cancer treatment that slows or halts the growth of hormone-sensitive cancers and is…
The third edition of the VHIOVida Festival, which was held on Saturday October 19, in Cabrils, brought together more than…
